Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines
Crossref DOI link: https://doi.org/10.1186/s12929-024-01000-1
Published Online: 2024-01-17
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Bin
Sim, Wei Kian
Shen, Tang-Long
Lim, Sai Kiang http://orcid.org/0000-0002-5752-3297
Text and Data Mining valid from 2024-01-17
Version of Record valid from 2024-01-17
Article History
Received: 6 July 2023
Accepted: 4 January 2024
First Online: 17 January 2024
Declarations
:
: Not applicable.
: SKL holds founder shares in Paracrine Therapeutics.